Oculis Completes Patient Enrollment in P-III (DIAMOND-1 & DIAMOND-2) Trials of OCS-01 for Diabetic Macular Edema
Shots:
- Oculis has completed pts enrollment in both P-III (DIAMOND-1 & DIAMOND-2) trials of OCS-01 in diabetic macular edema pts; trials to support NDA submission
- The trials will evaluate the efficacy & safety of OCS-01 in over 800 pts with DME across 119 sites in the US & other countries for 52wks.; topline data is expected in Q2’26, followed by regulatory submissions
- OCS-01 is a high-dose dexamethasone eye drop, developed using Oculis’ Optireach tech as a non-invasive retinal treatment for DME
Ref: Globenewswire | Image: Oculis
Related News:- Oculis Reports Results from P-II (ACUITY) Study of OCS-05 for Treating Acute Optic Neuritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
